Squarepoint’s Ocata Therapeutics OCAT Stock Holding History
Bought
Maintained
Sold
Squarepoint's OCAT Position: Q1 2016 in Review
Squarepoint sold out of Ocata Therapeutics (OCAT) in Q1 2016, closing a stake of 11,500 shares — an estimated $97K sold.
Squarepoint first reported a position in OCAT in Q4 2015 and held it in 1 quarter. The position peaked at $97K in Q4 2015. 1 fund tracked by Wall St. Rank holds OCAT as of Q1 2016.
- Squarepoint reported no remaining Ocata Therapeutics position as of Q1 2016 after selling out during the quarter.
- Squarepoint sold 11,500 Ocata Therapeutics shares in Q1 2016, an estimated $97K.
- Squarepoint first reported a position in Ocata Therapeutics in Q4 2015 and held it in 1 quarter.
- Squarepoint's Ocata Therapeutics position peaked at $97K in Q4 2015.
- 1 fund tracked by Wall St. Rank held Ocata Therapeutics as of Q1 2016.
Based on Squarepoint's 13F filing for Q1 2016, filed 16 May 2016.